{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-248755","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.923705+00:00","generated_at":"2026-05-30T07:38:30.699025+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Coya Therapeutics appoints Arun Swaminathan as CEO, Howard Berman becomes Executive Chairman effective Nov 1, 2024","bullets":["Swaminathan employment agreement provides $525,000 base salary, eligible for annual bonus up to 50% of base.","Berman employment agreement provides $420,000 base salary, eligible for annual bonus up to 50% of base.","Swaminathan becomes CEO on Nov 1, 2024; Berman resigns as CEO on Oct 31, 2024, remains on Board as Executive Chairman.","Severance: if terminated without cause, 12 months base salary continuation plus prorated bonus for each.","Non-compete for Swaminathan: 6 months post-termination, restricted to IL-2, CTLA-4 Ig, exosome product companies."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-248755","json":"https://secwatch.observer/filing/0001193125-24-248755.json","markdown":"https://secwatch.observer/filing/0001193125-24-248755.md","text":"https://secwatch.observer/filing/0001193125-24-248755.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000119312524248755/0001193125-24-248755-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000119312524248755/d840498d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:38:30.699025+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"122d5b3788","claim":"Howard Berman was appointed as Executive Chairman at Coya Therapeutics, Inc..","evidence_excerpt":"The Berman Employment Agreement provides for Dr. Berman to serve as Executive Chairman and provides for an annual base salary of $420,000.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835022/000119312524248755/0001193125-24-248755-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned as Chief Executive Officer and appointed as Executive Chairman"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"},{"claim_id":"737847db65","claim":"Arun Swaminathan was appointed as Chief Executive Officer at Coya Therapeutics, Inc..","evidence_excerpt":"Dr. Swaminathan was appointed as the Company’s Chief Executive Officer, effective November 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835022/000119312524248755/0001193125-24-248755-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}